Sona Nanotech Receives ‘Deprioritization’ from FDA; Health Canada Evaluation Continues

You may also like

Sona Nanotech’s THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech to Showcase its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Issued Patent and Appoints New Board Member

Sona Nanotech Grants Options